phosphosulindac

Phosphosulindac is a novel phospho-derivative of the non-steroidal anti-inflammatory drug (NSAID) sulindac, designed to enhance anti-cancer potency while minimizing the gastrointestinal and renal toxicities typically associated with traditional NSAIDs. Developed by researchers at Stony Brook University, phosphosulindac acts as a prodrug that releases sulindac or its metabolites, but also exhibits unique COX-independent mechanisms. It has been shown to inhibit the activation and nuclear localization of the transcription factor NFATc1 (Nuclear Factor of Activated T-cells), which is frequently upregulated in pancreatic and colorectal cancers. Preclinical studies indicate that phosphosulindac can significantly reduce tumor growth and increase the sensitivity of cancer cells to conventional chemotherapeutic agents.

Other names

phospho-sulindacsulindac-phospho-derivative